Background. IBR is a Bruton's tyrosine kinase inhibitor, and plays a key role in the treatment of CLL. In randomized clinical trials, <1% of IBR-treated CLL patients developed IFIs. However, several IFIs were reported with real-life use of IBR.
Methods. This is a retrospective observational study of all CLL patients (> 18 years) treated with IBR (2/2014-8/2018) at MD Anderson Cancer Center. We excluded patients with active IFI (proven and probable, EORTC/MSG criteria) at the start of IBR and patients with <6 months of follow-up.
Results. Of the 821 CLL IBR-treated patients, 24 developed probable or proven IFI (2.9%). Of these infections, 21 occurred within 30 days (d) of last IBR dose, while 3 IFIs occurred at 94, 135 and 221 d post IBR, respectively. The majority of patients with IFI were male (83%) with a median age of 66 years at IFI diagnosis. The median prior lines of therapy for CLL was 1 (range 0-7), with 29% receiving IBR as frontline treatment. Five patients had evidence of Richter's transformation at the time of IFI diagnosis, while two patients had prior stem cell transplant. The average time from start of IBR to diagnosis of IFI was 338 d, with only 7 cases of IFI within the first 3 months of IBR. The majority of IFIs were proven/probable aspergillosis (63%), including 9 cases of Aspergillus fumigatus. The remaining infections consisted of Cryptococcus neoformans (21%), Fusarium spp. (8%), with one case each of candidiasis, histoplasmosis, mucormycosis, and Pneumocystis jiroveci pneumonia. Three patients had evidence of poly-fungal IFI. The sites of infection were pulmonary (88%), blood (13%), CNS (13%), and sinus (8%). Five patients were diagnosed with disseminated IFI, including Cryptococcus spp. (2 cases), Rhizopus spp., Aspergillus spp., and Candida spp. The 42-day mortality rate post IFI diagnosis was 25%.
Conclusion. We report the largest single-center cohort of CLL patients on IBR to date. The IFI incidence of 2.9% (24/821) is consistent with most previous reports estimating a 0.5-4% incidence. In contrast to published reports, close to 1/3 of our patients with IFI received IBR as frontline therapy and most IFIs (71%) were diagnosed > 3 months after starting IBR. We are currently conducting a case-control comparison with IBR-treated CLL patients with no infection to uncover risk factors associated with IFIs in these patients.
Disclosures: Samuel L. Aitken, PharmD, Melinta Therapeutics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board. Background. Candida auris is an emerging new multi-drug-resistant fungal pathogen spreading globally. C. auris is associated with outbreaks due to the bloodstream, ear, and wound infections with a high mortality rate (30 to 60%). As part of our multi-pathogen surveillance system, we began screening for C. auris to understand the ecology, sources, and epidemiology of this important pathogen from leftover stool samples collected from hospitalized patients.
Isolation and Characterization of Candida auris From an Active Surveillance System in Texas
Methods. Four hundred and seventeen stool samples were collected, enriched in brain heart infusion broth for 2-3 days at 37°C, and sub-cultured onto selective Candida agar plates. Agar plates were incubated at 37°C for another 2-3 days and suspected Candida colonies were stocked for DNA extraction, PCR identification, and whole-genome sequencing. PCR amplicons were sequenced to confirm the identification C. auris. Enrichment samples were also screened by PCR to directly detect C. auris. Minimum inhibitory concentration (MIC) of various anti-fungal drugs was determined by the micro-dilution method using a commercial MIC plate (Sensititre "YeastOne").
Results. Three C. auris samples were identified by PCR (0.7%; 3/417) of which one was able to be cultured. The isolated strain was resistant to fluconazole, itraconazole, voriconazole, posaconazole, and caspofungin. WGS data analysis demonstrates our isolate has high similarity with the Pakistani strains.
Conclusion. We have detected C. auris from stool samples of hospitalized patients in Texas for the first time. WGS data indicate our isolate has high similarity with South Asian patient strains. Long-term surveillance of C. auris is essential to understand the infection or colonization sources and epidemiology of this newly emerging fungal pathogen.
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Poster Abstracts • OFID 2019:6 (Suppl 2) • S631 there is a need for better understanding of the effect of iatrogenic immunosuppression (present in most cases of IA) on such host response-driven biomarkers. Methods. Male BALB/c mice were separated into an Aspergillus fumigatus inhalational exposure group and a placebo group. These two groups were each subdivided into three additional sets based on immunocompromised status (no immunosuppression, cyclophosphamide, and corticosteroids) for a total of six experimental groups. Mice were sacrificed 4 days post-infection. Whole blood was assayed for transcriptomic responses via microarray. Bayesian techniques were utilized to develop classifiers of IA and leave one out cross-validation was used to estimate predictive probabilities.
Results. Aspergillus infection triggers a powerful response in non-IC hosts, with 2996 genes differentially expressed between IA and controls. We generated a 146-gene expression classifier able to discriminate between non-IC mice with IA and uninfected non-IC mice with 100% accuracy. However, the presence of immunosuppressive drugs exhibited a strong confounding effect on the transcriptomic classifier that was derived in the absence of immunosuppression. After controlling for the genomic effects of immunosuppressive drugs, we were able to generate a 187-gene classifier with a sensitivity of 100% and specificity of 97% across all IC states.
Conclusion. The host transcriptomic response to IA is robust and highly conserved. Pharmacologic perturbation of the host immune response unsurprisingly has powerful effects on gene expression-based classifier performance and must be taken into account when developing novel diagnostics. When appropriately designed, host-derived peripheral blood transcriptomic responses to IA demonstrate the ability to accurately diagnose Aspergillus infection, even in the presence of immunosuppression.
Disclosures. All authors: No reported disclosures. Background. Histoplasmosis is a serious fungal infection caused by the geographically restricted, dimorphic fungus Histoplasma capsulatum. In Canada, the geographic range of H. capsulatum is classically thought to be restricted to southern parts of Ontario and Quebec. Over the past decade, histoplasmosis has occasionally been diagnosed in patients in Alberta without travel to areas of known geographic risk (Figure 1) . We studied the epidemiology and geographic distribution of histoplasmosis in Alberta to assess evidence for locally-acquired infections.
Histoplasmosis
Methods. We retrospectively reviewed all laboratory-confirmed (culture, antigen and/or immunodiffusion positive) cases of histoplasmosis diagnosed from January 1, 2011 to June 30, 2018. Data collected by public health and clinical charts were reviewed for clinical presentation, exposure and travel histories, and geographic distribution of cases. Cases of histoplasmosis in patients who had not left Alberta or associated with a local point source were classified as definite local acquisition; cases in patients with remote travel but with local exposures and appropriate timing of disease onset were deemed "probable" cases of local infection. University of Alberta's Research Ethics Board approved this study.
Results. We identified 45 laboratory-confirmed cases of histoplasmosis, including 17 cases that were locally acquired. Among these, there were 12 cases of definite local acquisition, including 8 patients from 3 point-source outbreaks-all involving exposure to bats and/or their droppings in chimneys or attics of private dwellings or churchesand 4 sporadic cases in patients who had never traveled. Of the other 5 cases probably acquired in Alberta, patients had previously traveled (n = 4) or travel history was incomplete (n = 1) but local exposures preceding infection were considered compelling. The mean incidence rate of locally acquired infection was 0.062/100,000 population with incidence increasing since 2014. Table 1 shows features of locally acquired cases.
Conclusion. This study, for the first time, establishes Alberta as a region of geographic risk for histoplasmosis. The diagnosis should be considered in patients with compatible symptoms and exposure history, even in the absence of travel.
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